ReviewEuropean respiratory review : an official journal of the European Respiratory Society2019
Severe T2-high asthma in the biologics era: European experts' opinion.
Review in European respiratory review : an official journal of the European Respiratory Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed.
- Association of Easier Biologic Access with Remission and Other Clinical Outcomes in Severe Asthma: A Global Real-World Study.Journal of asthma and allergy · 2026Article
- Real-world evidence of tezepelumab for severe asthma: a retrospective multicentre cohort.ERJ open research · 2025Article
- Development and validation of a Delphi consensus-based questionnaire for the multidisciplinary management of type 2 inflammation-related diseases.Frontiers in allergy · 2025Article
- Efficacy of dupilumab and risk factors for dupilumab-induced hypereosinophilia in severe asthma: a preliminary study from China.Annals of medicine · 2024Article
- Endotypes of severe neutrophilic and eosinophilic asthma from multi-omics integration of U-BIOPRED sputum samples.Clinical and translational medicine · 2024Article
- Thymic Stromal Lymphopoietin and Tezepelumab in Airway Diseases: From Physiological Role to Target Therapy.International journal of molecular sciences · 2024Review
- Tezepelumab: patient selection and place in therapy in severe asthma.The Journal of international medical research · 2024Review
- Obesity and Insulin Resistance in Asthma Pathogenesis and Clinical Outcomes.Biomedicines · 2024Review
- Real-World Characteristics of Patients with Severe Asthma prior to Starting Dupilumab: The ProVENT Study.Respiration; international review of thoracic diseases · 2024Article
- Personalized Medicine in Severe Asthma: From Biomarkers to Biologics.International journal of molecular sciences · 2023Review
- Platelet Serotonin (5-HT) Concentration, Platelet Monoamine Oxidase B (MAO-B) Activity andBiomolecules · 2023Article
- Non-typeableEuropean respiratory review : an official journal of the European Respiratory Society · 2022Review
- T2-high asthma phenotypes across lifespan.The European respiratory journal · 2022Article
- Review
- DNA methylation signatures in airway cells from adult children of asthmatic mothers reflect subtypes of severe asthma.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Novel potential treatable traits in asthma: Where is the research taking us?The journal of allergy and clinical immunology. Global · 2022Review
- Effects of anti-IL5 biological treatments on blood IgE levels in severe asthmatic patients: A real-life multicentre study (BIONIGE).Clinical and translational allergy · 2022Article
- Small Airway Disease in Pediatric Asthma: the Who, What, When, Where, Why, and How to Remediate. A Review and Commentary.Clinical reviews in allergy & immunology · 2022Review
- Plasma Metabolites and Gut Microbiota Are Associated With T cell Imbalance in BALB/c Model of Eosinophilic Asthma.Frontiers in pharmacology · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The European Respiratory Biologics Forum gathered participants from 21 countries in Madrid, Spain, to discuss the management and treatment of severe asthma in the era of biologics. The current insights on the pathophysiology of severe asthma were discussed, as well as the role of respiratory biologics in clinical practice and strategies for eliminating chronic use of oral corticosteroids. The participants also highlighted the key challenges in identifying patients with severe asthma based on phenotypes, biomarkers and treatable traits, and the existing problems in patient referral to specialist care. The monitoring of treatment was debated and the need for a change towards precision medicine and personalised care was emphasised throughout the meeting. This review provides a summary of the discussions and highlights important concerns identified by the participants regarding the current management of severe asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.